RecruitingNCT06541132

Positive Association of US-FLI With the Severity of CAD

Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease

Sponsor

Chongqing Medical University

Enrollment

190 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Ultrasonography Metabolic Dysfunction-associated Fatty Liver Disease Coronary Artery Disease of Significant Bypass Graft SYNTAX Score

Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Observational study without human intervention for people with coronary artery disease of significant bypass graft, metabolic dysfunction-associated fatty liver disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.